Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Change in Accured Expenses (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Change in Accured Expenses for 2 consecutive years, with -$129000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Change in Accured Expenses fell 637.5% year-over-year to -$129000.0, compared with a TTM value of -$246000.0 through Jun 2025, changed N/A, and an annual FY2024 reading of $404000.0, down 47.67% over the prior year.
  • Change in Accured Expenses was -$129000.0 for Q2 2025 at Kairos Pharma, up from -$187000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $310000.0 in Q1 2024 and bottomed at -$191000.0 in Q3 2024.